



21 December 2017

**cyclo**medica  
**technegas**  
**ultralute**

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
www.cyclopharm.com.au

## FNN INTERVIEW AND PRESENTATION

Further to Cyclopharm Limited's (ASX:CYC) ASX announcement of 12 December 2017, the Company is pleased to advise that videos of its FNN Investor Event presentation and an interview with Managing Director, James McBryer, following the presentation are available to be viewed at:

**FNN Investor Event Presentation Video:**

<http://cyclopharm.com.au/2017/12/20/cyclopharm-asx-cyc-presentation-fnn-investor-event-dec-2017-sydney/>

**FNN Interview with Mr James McBryer:**

<http://cyclopharm.com.au/2017/12/19/james-mcbrayer-talks-lung-disease-screening/>

**For more information, please contact:**

Mr James McBryer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

**Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

**Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

**Ultralute™**

Cyclopharm's patented nuclear medicine technology Ultralute™ extends the useful life of Molybdenum-99 (Mo-99) generators by up to 50%. This technology potentially gives nuclear medicine departments the ability to dramatically improve operating efficiencies and health outcomes for patients. Mo-99 generators are used in diagnostic imaging to harvest Technetium-99m, or Tc-99m, which is the primary isotope used in diagnostic imaging throughout the world. This isotope accounts for approximately 80% of all nuclear medicine diagnostic imaging procedures.